McCormick, Kevin D. et al. published their patent in 2008 |CAS: 50743-01-6

The Article related to benzoxazine benzothiazine quinoxaline preparation adrenoceptor agonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 5-Bromo-1H-imidazole-4-carbaldehyde

On August 21, 2008, McCormick, Kevin D.; Boyce, Christopher W.; Shih, Neng-Yang; Aslanian, Robert G.; Fevrier, Salem; Mangiaracina, Pietro; De Lera Ruiz, Manuel; Yu, Younong; Zheng, Junying; Huang, Chia-Yu; Liang, Bo; Liu, Rong-Qiang; Liu, Ruiyan; Guise Zawacki, Lisa published a patent.Safety of 5-Bromo-1H-imidazole-4-carbaldehyde The title of the patent was 3,4-Dihydro-1,4-benzoxazine, 3,4-dihydro-1,4-benzothiazine and 1,2,3,4-tetrahydroquinoxaline derivatives as alpha2C adrenoreceptor agonists and their preparation. And the patent contained the following:

The invention relates to a class of benzomorpholine and benzothiomorpholine compounds of formula I useful as alpha2C adrenergic receptor agonists, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the alpha2C adrenergic receptor agonists, such as allergic rhinitis, congestion, pain, diarrhea, glaucoma, congestive heart failure, cardiac ischemia, manic disorders, depression, anxiety and schizophrenia. Compounds of formula I wherein A is (un)substituted 5-membered heterocyclic ring; X is O, S, SO, SO2 and NH and derivatives; J1, J2, J3 and J4 are independently, N, NO and CR2, with the proviso that 0-3 of J1-J4 are N; R2 is H, OH, halo, CN, NO2, etc.; Y is (CH2)1-3; each R3 is H, halo, =O, alkyl, alkoxy, alkenyl, etc.; R4 is H, CN, halo, alkyl, alkoxy, alkenyl, etc.; n is 1-5; m is 0-4; and their pharmaceutically acceptable salts, esters, solvates and prodrugs thereof are claimed. Example compound II was prepared by reductive alkylation of 3,4-dihydro-2H-1,4-benzoxazine with imidazole-4-carboxaldehyde. All the invention compounds were evaluated for their δΌͺ2C adrenoreceptor agonistic activity (some data given). The experimental process involved the reaction of 5-Bromo-1H-imidazole-4-carbaldehyde(cas: 50743-01-6).Safety of 5-Bromo-1H-imidazole-4-carbaldehyde

The Article related to benzoxazine benzothiazine quinoxaline preparation adrenoceptor agonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 5-Bromo-1H-imidazole-4-carbaldehyde

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem